Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET
Company Participants
Ted Jenkins - Vice President, Investor Relations & Strategic Finance
Ankit Mahadevia - Chief Executive Officer
Kamal Hamed - Chief Medical Officer
Sat Shukla - Chief Financial Officer
Conference Call Participants
Gavin Clark-Gartner - Evercore ISI
Louise Chen - Cantor
Ritu Baral - Cowen
Operator
Good afternoon and welcome to the Spero Therapeutics' Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode. Following the company's formal remarks, we will open up the call for questions.
Please be advised that this call is being recorded and a replay will be available. You can find information on the replay and further information related to today's announcement on the Spero Therapeutics website, www.sperotherapeutics.com.
At this time, I would like to turn the conference call over to Ted Jenkins, Vice President Investor Relations and Strategic Finance at Spero Therapeutics. Mr. Jenkins please go ahead.
Ted Jenkins
Thank you, operator and thank you all for participating in today's conference call. This afternoon Spero Therapeutics released financial results and provided a pipeline update for the third quarter of 2022. A press release is available on the Investor page of the Spero Therapeutics website.
Before we begin, I'd like to remind you that some of the information presented on this conference call contains forward-looking statements based on our current expectations including statements about the future development and commercialization of SPR720, SPR206, and tebipenem HBr; and the design initiation timing, progress, and results of the company's preclinical studies and clinical trials and its research and development programs; management's assessment of the results of such preclinical studies and clinical trials; the company's cash forecast and anticipated expenses and its sufficiency of its cash resources.
Such forward-looking statements are not a guarantee of performance and the company's actual results could differ materially from those contained in such statements. Several factors that could cause or contribute to such differences are described in detail in Spero Therapeutics' filings with the SEC including in the risk factor section of our quarterly report on Form 10-Q for the quarter ended September 30th, 2022 filed today.
These forward-looking statements speak only as of the date of this conference call and the company undertakes no obligation to publicly update any forward-looking statements or supply new information regarding the company after the date of today's call.